Cachectin/tumor necrosis factor regulates hepatic acute-phase gene expression

J Clin Invest. 1986 Nov;78(5):1349-54. doi: 10.1172/JCI112721.

Abstract

The monokine, cachectin/tumor necrosis factor (TNF) differs from interleukin 1 (IL-1) in primary structure and in recognition by a distinct cellular receptor. It does, however, encode effector functions that are similar to those of IL-1 and characteristic of the host response to inflammation or tissue injury. Accordingly, we examined the possibility that recombinant-generated human TNF regulates hepatic acute-phase gene expression. In picomolar concentrations, TNF mediated reversible, dose- and time-dependent increases in biosynthesis of complement proteins factor B and C3, alpha 1 antichymotrypsin, and decreases in biosynthesis of albumin and transferrin in human hepatoma cell lines (Hep G2, Hep 3B). Biosynthesis of complement proteins C2 and C4, and alpha 1 proteinase inhibitor were not affected by TNF. TNF also increased factor B gene expression, but had no effect on C2 gene expression, in murine fibroblasts transfected with cosmid DNA bearing the human C2 and factor B genes. The effect of TNF on acute-phase protein expression (C3, factor B, albumin) was pre-translational as shown by changes in specific messenger RNA content.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Acute-Phase Proteins / genetics*
  • Animals
  • Carcinoma, Hepatocellular
  • Cell Line
  • Genes / drug effects*
  • Glycoproteins / pharmacology*
  • Humans
  • Interleukin-1 / physiology
  • L Cells / metabolism
  • Liver / drug effects
  • Liver / metabolism*
  • Liver Neoplasms
  • Mice
  • Recombinant Proteins / pharmacology
  • Transcription, Genetic / drug effects
  • Tumor Necrosis Factor-alpha

Substances

  • Acute-Phase Proteins
  • Glycoproteins
  • Interleukin-1
  • Recombinant Proteins
  • Tumor Necrosis Factor-alpha